An emerging objective in the IBD community is to gear the findings from genome-wide association studies towards achieving precision medicine. The main goal of this new model of disease management is to adapt clinical practice to the needs of each patient. This includes, among others, obtaining more detailed characterizations of disease presentation at diagnosis, better prediction of disease prognosis that permits to anticipate and adapt management to variations in symptomatology, and tailoring treatment to individual needs. In this chapter, we will introduce the methodology for estimation of disease risk using genetic data from individuals and discuss the potential and main challenges for using genomic risk profiling as a predictive tool that can pave the way for adoption of precision medicine-based approaches in the clinical management of IBD.
CITATION STYLE
Marigorta, U. M. (2019). Genetic risk prediction in IBD. In Molecular Genetics of Inflammatory Bowel Disease (pp. 141–156). Springer. https://doi.org/10.1007/978-3-030-28703-0_7
Mendeley helps you to discover research relevant for your work.